Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2009
-
By Donald Zuhn — Reflecting upon the events of the past twelve months, Patent Docs presents its third annual list of top biotech/pharma stories. For 2009, we identified ten top stories that we covered on Patent Docs last year. Today, we count down stories #10, #9, and #8. On Sunday, we will present stories…
-
By Donald Zuhn — Senate Passes Patient Protection and Affordable Care Act On Christmas Eve, the Senate passed the Patient Protection and Affordable Care Act (H.R. 3590) by a 60-39 vote. Independent Senators Joe Lieberman (I-CT) and Bernard Sanders (I-VT) joined all 58 Democratic Senators in voting for the bill. All of the Republican…
-
By Donald Zuhn — Over the past five months, biotech and pharma companies have increasingly turned to the stock market for much needed infusions of capital. In August, Nashville-based Cumberland Pharmaceuticals snapped a two-year industry dry spell when it conducted an initial public offering (IPO) that raised $85 million (see "Is Biotech/Pharma Beginning to…
-
By Kevin E. Noonan — Gene patenting, and proposed bans on the practice, have garnered several newspaper reports and responses from professional groups around the world. Australian Senate Panel Debates Gene Patenting The Community Affairs Committee of the Australian Senate is investigating whether genes should be patentable in that country, according to a December…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Abbott Laboratories, Inc. et al. v. Apotex Inc. et al.1:09-cv-07968; filed December 22, 2009 in the Northern District of Illinois • Plaintiff: Abbott…
-
By Sarah Fendrick — On December 18, 2009, the U.S. Patent and Trademark Office announced the launch of an interactive patent pendency model (PPM). The PPM enables users to see how overall application pendency is affected by the number of examiner hires per year, the amount of overtime worked, and patent filing levels. In…
-
January 6-10, 2010 – 27th Annual National CLE Conference (Law Education Institute, Inc.) – Vail, CO January 20-21, 2010 – Life Sciences IP Due Diligence (American Conference Institute) – New York, NY January 25-26, 2010 – European Pharmaceutical Regulatory Law Boot Camp (American Conference Institute) – New York, NY January 26-27, 2010 – Advanced In-House…
-
The authors and contributors of Patent Docs wish their readers and families a Happy Holidays. Publication of Patent Docs will resume on December 27th.
-
By Kevin E. Noonan — In what may be considered a softening (or at least a change) in its approach to protecting its patented technology, Monsanto announced that it would not enforce any contractual provisions regarding its Roundup Ready® transgenic seed (that preclude growers from replanting genetically-engineered seeds) once the patents on that technology…
-
By Kevin E. Noonan — The latest challenge to Amgen's erythropoietin (EPO) franchise ended today, when Hoffman-La Roche agreed to keep its pegylated derivative of human EPO, Mircera®, off the market until July 1, 2014. The U.S. Food and Drug Administration granted approval for Roche to market Mircera® in November, 2007 (it has already…
Patent Docs 